




BMJ Open Healthcare resource utilisation and costs of hospitalisation and primary care among adults with COVID-19 in England: a population-based cohort study

Jingyan Yang,^{1,2} Kathleen Michelle Andersen ¹, Kiran K Rai,³ Theo Tritton,³ Tendai Mugwagwa,¹ Maya Reimbaeva,¹ Carmen Tsang,⁴ Leah J McGrath,¹ Poppy Payne,³ Bethany Emma Backhouse ³, Diana Mendes,⁴ Rebecca Butfield,⁴ Kevin Naicker,⁴ Mary Araghi,⁴ Robert Wood ³, Jennifer L Nguyen¹

To cite: Yang J, Andersen KM, Rai KK, *et al.* Healthcare resource utilisation and costs of hospitalisation and primary care among adults with COVID-19 in England: a population-based cohort study. *BMJ Open* 2023;**13**:e075495. doi:10.1136/bmjopen-2023-075495

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-075495>).

Received 10 May 2023
Accepted 11 December 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Pfizer Inc, New York, New York, USA

²The Institute for Social and Economic Research and Policy, Columbia University, New York, New York, USA

³Adelphi Real World, Bollington, UK

⁴Pfizer, Tadworth, UK

Correspondence to

Dr Jingyan Yang;
jingyan.yang@pfizer.com

ABSTRACT

Objectives To quantify direct costs and healthcare resource utilisation (HCRU) associated with acute COVID-19 in adults in England.

Design Population-based retrospective cohort study using Clinical Practice Research Datalink Aurum primary care electronic medical records linked to Hospital Episode Statistics secondary care administrative data.

Setting Patients registered to primary care practices in England.

Population 1 706 368 adults with a positive SARS-CoV-2 PCR or antigen test from August 2020 to January 2022 were included; 13 105 within the hospitalised cohort indexed between August 2020 and March 2021, and 1 693 263 within the primary care cohort indexed between August 2020 and January 2022. Patients with a COVID-19-related hospitalisation within 84 days of a positive test were included in the hospitalised cohort.

Main outcome measures Primary and secondary care HCRU and associated costs ≤4 weeks following positive COVID-19 test, stratified by age group, risk of severe COVID-19 and immunocompromised status.

Results Among the hospitalised cohort, average length of stay, including critical care stays, was longer in older adults. Median healthcare cost per hospitalisation was higher in those aged 75–84 (£8942) and ≥85 years (£8835) than in those aged <50 years (£7703). While few (6.0%) patients in critical care required mechanical ventilation, its use was higher in older adults (50–74 years: 8.3%; <50 years: 4.3%). HCRU and associated costs were often greater in those at higher risk of severe COVID-19 than in the overall cohort, although minimal differences in HCRU were found across the three different high-risk definitions. Among the primary care cohort, general practitioner or nurse consultations were more frequent among older adults and the immunocompromised.

Conclusions COVID-19-related hospitalisations in older adults, particularly critical care stays, were the primary drivers of high COVID-19 resource use in England. These

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ To the best of our knowledge, this is the first study to assess healthcare resource utilisation (HCRU) and costs associated with COVID-19, separately, in the primary and secondary care settings within England.
- ⇒ Our results may inform resource allocation across care settings to optimise COVID-19 management.
- ⇒ Hospitalisation status is unknown for patients after April 2021; therefore, secondary care HCRU and costs during the Omicron predominance period were not described.
- ⇒ Due to data latency accident and emergency and outpatient attendances were not assessed.

findings may inform health policy decisions and resource allocation in the prevention and management of COVID-19.

INTRODUCTION

COVID-19 is a highly infectious respiratory illness caused by the SARS-CoV-2. Globally, ~670 million cases and ~6.9 million deaths related to COVID-19 have been recorded as of 9 March 2023.¹ Within England, as of 1 March 2023 there have been approximately 20.5 million cases, 982 000 hospitalisations and 186 000 associated deaths.² The clinical presentation of COVID-19 ranges from asymptomatic to critical illness, where mild or uncomplicated illness is commonly managed in primary care and severe COVID-19 managed in the hospital setting.^{3 4} While the majority experience few symptoms or mild to moderate COVID-19, some patients require medical intervention, including respiratory support and intensive care admission.⁵ The risk of worse outcomes, for example, hospitalisation



and death, is greater for older adults, smokers, those who are obese, have a compromised immune system and/or have certain comorbidities such as hypertension and lung disease.^{6,7} As such, the Joint Committee on Vaccination and Immunisation (JCVI) recommended the prioritisation of COVID-19 vaccination in specific groups (based on age, those clinically extremely vulnerable, underlying health conditions, pregnancy and working in health and social care).⁸

While the vaccination roll-out has substantially reduced COVID-19-associated morbidity and mortality, COVID-19 remains a significant burden on the UK healthcare system. According to a report published by the UK's Department of Health and Social Care assessing the impacts during the Omicron wave in England, COVID-19 has led to longer waits for elective and emergency visits in the secondary care setting, and across the pandemic COVID-19 has reduced or delayed appointments and referrals in primary care, potentially resulting in a worsened state of health for some primary care patients.⁹

In addition to the health impact of COVID-19, several studies in the USA have quantified the economic burden of COVID-19-related hospitalisations,¹⁰⁻¹² and have reported higher costs among those with health complications. Studies quantifying the economic burden of COVID-19 in the UK are scarce; of the 37 studies identified within a systematic review quantifying the economic impact of COVID-19, five focused on UK-based data, of which two assessed direct healthcare burden attributed to patient care, three assessed the macroeconomic impact of the epidemic and its associated policies and two assessed the costs associated with COVID-19.¹³ Only two studies reported use of electronic health records, with no studies reporting the use of general practitioner (GP) appointments data. Keogh-Brown *et al* report that the impact of COVID-19 on the UK economy was approximately a loss of £40 billion in 2020.¹⁴ However, much of these costs were related to reduced labour (~£39 billion), and while overall hospital and intensive care costs were estimated (~£1 billion), these focused on the health-related economic impact on the UK economy, rather than individual-level costs to the National Health Service (NHS) to manage patients with COVID-19. Furthermore, to our knowledge, no studies have reported direct medical costs within the primary care setting. By addressing these data gaps within the literature, we will provide valuable evidence to support health policy decisions on public health interventions and healthcare resource allocation in the prevention and management of COVID-19.

Aims and objectives

This study aimed to quantify healthcare resource utilisation (HCRU) and costs associated with COVID-19 in adults in England, by age and according to risk of severe COVID-19 and immunocompromised status, separately for those with and without hospitalisation records, using UK primary care data, linked to secondary care data when available.

METHODS

Study design and setting

We conducted a population-based retrospective cohort study using data obtained from the Clinical Practice Research Datalink (CPRD) Aurum primary care database¹⁵ and, when available, linked secondary care data (Hospital Episode Statistics Admitted Patient Care (HES APC) dataset).¹⁶ The May 2022 release of CPRD Aurum was used; the latest data from CPRD Aurum cover the period of January 1995 to April 2022,^{17,18} while HES APC covers April 1997 to March 2021.¹⁶ The study design and methods have been described elsewhere.¹⁹ A study design schematic is provided in online supplemental eFigure 1.

Two distinct patient cohorts were created to describe the economic burden of the acute phase of COVID-19 (≤ 4 weeks following positive test) among adults in the UK:

1. *Hospitalised cohort*: Patients who had a positive SARS-CoV-2 PCR or antigen test, or a recorded clinical diagnosis of COVID-19, in their GP record between 1 August 2020 and 31 March 2021 and had a COVID-19-related hospitalisation within 84 days after their positive test result. The index period start date was chosen to align with when it became mandatory for NHS Test and Trace to report positive PCR test results to the patient's GP practice, from 20 July 2020 onwards²⁰; the end date was determined by the end of data availability within HES APC. Patients in this cohort may have also received COVID-19 care outside of the hospital setting, for example, primary care consultations.
2. *Primary care cohort*: Patients who had a positive SARS-CoV-2 PCR or antigen test, or a recorded clinical diagnosis of COVID-19, in their GP record. For persons diagnosed between 1 August 2020 and 31 March 2021, they were included in this cohort if they did not have a record for a COVID-19-related hospitalisation within 84 days of their positive test result. All persons diagnosed with COVID-19 on or after 1 April 2021 were included in this cohort, as this was a period of time for which CPRD did not have hospitalisation data available. The index period end date, January 2022, was determined by the overall cohort design.¹⁹

Population

Patients aged ≥ 18 years were included in this study. Further details on the eligibility criteria are cited elsewhere.¹⁹ In brief, this study included patients who had: (1) a confirmed COVID-19 episode recorded in CPRD Aurum, where the first date of COVID-19 diagnosis (ie, index date) was observed in the index period, (2) a minimum registration period of 12 months at their current GP practice prior to the index date, (3) data considered of acceptable research quality as defined by CPRD²¹ and (4) eligible for linkage to HES. Patients were excluded if they had a record for a COVID-19-related hospitalisation or death prior to their GP-recorded date of COVID-19 diagnosis. COVID-19 episodes starting prior to August 2020, from which point capture of COVID-19 test results within

GP patient records was considered nearly complete, were not included in the study.

Demographic and clinical characteristics

Sociodemographic characteristics at index included age, sex, region of GP practice, ethnicity (using patient history), social deprivation (measured using the Index of Multiple Deprivation (IMD) 2019 score), smoking status (using patient history) and body mass index (BMI) within 2 years of the index date. Clinical characteristics included Quan-Charlson Comorbidity Index (CCI) 2005²² within 2 years of index, and vaccination status according to immunocompromised status at index. Vaccination status at index for immunocompetent patients was defined according to whether they had received 0 dose (unvaccinated), 1 primary dose, 2 primary doses or any booster dose. For immunocompromised patients, vaccination status was defined according to whether they had received 0 dose (unvaccinated), 1 primary dose, 2 primary doses, 3 primary doses or any booster dose. A patient was considered vaccinated starting from 14 days after dose receipt, and doses were required to be separated by at least 21 days. Disease severity among the hospitalised cohort was assessed using the Ordinal Scale for Clinical Improvement within WHO's COVID-19 Therapeutic Trial Synopsis,²³ based on the highest level of care received during the hospitalisation following mutually exclusive categories: (1) hospitalised, no oxygen therapy; (2) oxygen by mask or nasal prongs; (3) non-invasive ventilation or high-flow oxygen; (4) intubation and mechanical ventilation (MV); and (5) ventilation and additional organ support. Further details on definitions and operationalisation of code lists are described elsewhere.¹⁹

Outcomes and follow-up

Healthcare resource utilisation

All COVID-19-related HCRU and associated costs to the NHS in the 4 weeks including and following the index date were calculated and reported for the following elements of HCRU:

Medication use: Medications that were prescribed within primary care were considered to be COVID-19 related when prescribed on the same day as a COVID-19 diagnosis (see online supplemental eTable 1).^{24 25}

Primary care consultations: GP or nurse consultations with a diagnostic code of COVID-19 were reported separately for face-to-face (F2F) and telephone consultations. This was defined as a maximum of one visit of each format per person per day, and any additional visits were considered as data capture errors.

Hospitalisations: Hospital admissions with a COVID-19 primary diagnosis were assessed within the hospitalised cohort. Additionally, the mean (SD) and median (IQR) length of stay (LoS) per admission was assessed and reported separately for time spent in hospital from admission to discharge as well as time spent in high dependency/intensive care units (HDUs/ICUs). Whether MV treatment was received was also reported. In the event of

multiple hospitalisations (or for critical care, HDU/ICU stays) during the acute COVID-19 phase, the average LoS per person, rather than the cumulative total, was used.

Direct healthcare costs: Costs were described for patients with one or more events of a given type only, that is, resource users, and persons without utilisation were not included in the distributions of costs presented. The estimation of costs associated with hospitalisations was based on the National Schedule of NHS Costs (2020/2021) which reports costs of admitted patient care by Healthcare Resource Group in England.²⁶ In order to estimate the cost per hospitalisation, all finished consultant episodes (FCEs: the time a patient spends in the care of one consultant within their hospitalisation) within one admission were accounted to derive the total spell (hospitalisation) cost.²⁷ In the event that a given person had multiple hospitalisations during the acute phase, cost per day estimates were obtained by dividing total hospitalisation costs by total LoS per patient.

Primary care consultations (including GP or nurse visits) were costed using information compiled and provided by the Personal Social Services Research Unit.²⁸ The direct healthcare cost for each prescription written in primary care was calculated via the application of cost per unit from the NHS Drug Tariff.²⁹

Statistical analysis

This descriptive study included all patients who met the study eligibility criteria. This study did not involve hypothesis testing; therefore, formal sample size calculations were not performed. Means and SD, or median and lower and upper quartiles (Q1, Q3) were calculated for numerical variables, with frequency counts and percentages presented for categorical variables. Per the design of the study, all results were presented separately for the hospitalised cohort and primary care cohorts.

Stratifying variables

All outcomes were evaluated by age, high risk status and immunocompromised status, as previous studies have shown that healthcare utilisation can differ by age and clinical status.^{30 31} Age group categories were based on the COVID-19 vaccination roll-out strategy in the UK: 18–49; 50–64; 65–74; 75–84; and 85+. Three separate definitions were used to define persons at greater risk of severe COVID-19: (1) the McInnes Advisory Group highest risk group (a list of conditions to identify persons at the very highest risk of COVID hospitalisation and death, as defined by an advisory group chaired by Professor Iain McInnes and supported by the NHS England RAPID-C19 team (the McInnes Advisory Group)),³² (2) eligibility for the PANORAMIC study (a randomised trial of antiviral therapeutic agents including patients who were deemed at a higher risk of hospitalisation and death (PANORAMIC))³³ and (3) the UK Health Security Agency clinical groups, outlined in COVID-19: the Green Book, chapter 14a (JCVI's COVID-19 vaccination

prioritisation criteria) (the Green Book).⁸ The code lists for each high risk definition were developed using reproducible search terms with multiple reviewers, have been previously described and published.¹⁹ For immune system status, patients were classified as immunocompromised at the time of receipt of first COVID-19 vaccine dose if they had one or more codes meeting Davidson *et al's* definition of immunocompromised status.³⁴ All analyses were conducted in SAS V.9.4 (SAS Institute).

Patient and public involvement

There was no direct involvement of patients and public in this study. However, we aim to disseminate the findings through appropriate channels.

RESULTS

Patient sociodemographic and clinical characteristics

A total of 1 706 368 adult COVID-19 cases were included in this study. Of the 471 128 patients diagnosed between 1 August 2020 and 31 March 2021, a total of 13 105 (2.8%) were included in the hospitalised cohort; 1 693 263 were included in the primary care cohort. **Table 1** summarises the baseline patient characteristics across the hospitalised and primary care cohorts.

Among the hospitalised cohort, the majority (n=9978; 76.1%) of patients were aged ≥ 50 years (mean age (SD): 60.7 (16) years), more than half (n=7504; 57.3%) were male, 66.9% were of white ethnic origin and 46.6% (n=6102) lived in areas with greatest deprivation (IMD quintiles 4 and 5).

Of those with known smoking status, 56.7% (n=5500) had a history of smoking. Over half (n=6974; 53.2%) were overweight or obese according to BMI, and among those with a BMI record, this increased to 84.8%. Over half of patients (n=7078; 54.0%) had a CCI score of 0. The majority (98.6%) of the hospitalised cohort were defined as immunocompetent in baseline, of whom 98.1% were unvaccinated at index (n=12 684; 98.1%).

The proportions of patients meeting the McInnes Advisory Group, PANORAMIC and the Green Book definitions, respectively, were 33.0% (n=4323), 84.0% (n=11 011) and 40.8% (n=5341). Most (73.3%) patients did not receive oxygen therapy during their hospitalisation, and few patients (n=847; 6.5%) received intubation or ventilation support.

Sociodemographic characteristics of the primary care cohort differed numerically from the hospitalised cohort: the majority (n=1 161 843; 68.6%) of patients were aged < 50 years (mean age (SD): 42.3 (15.8) years), more than half (n=928 546; 54.8%) were female and patients were relatively evenly spread across socioeconomic quintiles. However, the distribution across ethnicity groups was similar to the hospitalised cohort.

When considering the clinical characteristics, among those with known smoking status 52.0% had a smoking history, and 24.4% were overweight or obese (n=414 037). Most patients (n=1 462 791; 86.4%) had a CCI score of

0. Unlike the hospitalised cohort, vaccination status was more varied; among the 1 629 716 (96.2%) immunocompetent patients in the primary care cohort, 40.5% were unvaccinated.

Relatively fewer patients than in the hospitalised cohort were at risk of severe COVID-19 across all three definitions (McInnes Advisory Group: n=250 329, 14.8%; PANORAMIC: n=691 593, 40.8%; Green Book: n=212 556, 12.6%).

HCRU and associated costs

Hospitalised cohort

The median total spell LoS, including both general ward as well as critical care admission, was 6.0 days. The LoS was longer for older patients; median LoS was 5.0 days for those aged 18–49 years, 6.0 days for aged 50–64 years and 8.0 days for aged > 65 years (**table 2**). When stratified by risk of severe COVID-19, LoS was similar across definitions (median 7.0 days (Q1: 4.0, Q3: 12.0)). The median LoS was 1 day longer in immunocompromised patients (7.0 (4.0, 12.0)) compared with those immunocompetent (6.0 (4.0, 12.0)) (see online supplemental eTable 2 for full details).

Of the 13 105 hospitalised patients, 1934 (14.8%) were admitted to critical care. The median LoS in critical care was 8.0 days. The proportion requiring critical care, as well as LoS, was greatest among the aged 50–64 and 65–74 groups. Critical care LoS was similar for persons meeting each risk definition as well as by immunocompromised status when compared with the overall cohort.

Median healthcare cost per hospitalisation was lower in those aged 18–49 years (£7703) than in those aged 75–84 years (£8942) and ≥ 85 years (£8835), and was similar across the risk definitions (£8727) and immunocompromised status (£8727 in the immunocompromised and immunocompetent groups) (see online supplemental eTable 3 for full details). The median non-critical care costs followed similar patterns, whereas median observed critical care costs were higher among immunocompetent patients (£17 439) than among immunocompromised patients (£14 551) (**table 3**). The mean number of FCEs per hospitalisation was 2.0, with FCEs ranging between 1–7 for immunocompromised patients and 1–16 patients for immunocompetent patients (data not shown in tables).

Median costs of critical care requiring MV were broadly similar across all stratifications. Overall, the proportion of hospitalised patients who received MV was low (n=792; 6.0%) and increased with age (4.3% for ages 18–49, 8.2% for ages 50–64 and 8.6% for ages 65–74 years), but decreased after age 74. MV use varied slightly across the risk definitions, with the highest use in the PANORAMIC group (6.5%), and lowest in the Green Book group (5.2%). Among people who received MV, the median length of ventilation was 1.0 day; this did not differ across stratifications (see online supplemental eTable 2).

Table 1 Demographic and clinical characteristics of the study population at baseline

Characteristics	Hospitalised cohort (n=13 105) n (%)	Primary care cohort (n=1 693 263) n (%)
Age, years		
Mean (SD)	60.7 (16.0)	42.3 (15.8)
18–49	3127 (23.9)	1 161 843 (68.6)
50–64	4844 (37.0)	379 528 (22.4)
65–74	2386 (18.2)	92 573 (5.5)
75–84	1690 (12.9)	40 481 (2.4)
≥85	1058 (8.1)	18 838 (1.1)
Sex		
Male	7504 (57.3)	764 687 (45.2)
Female	5601 (42.7)	928 546 (54.8)
Unknown	0	30 (<0.1)
GP practice region		
North East	465 (3.6)	65 755 (3.9)
North West	2872 (21.9)	363 770 (21.5)
Yorkshire and the Humber	339 (2.6)	53 777 (3.2)
East Midlands	213 (1.6)	38 663 (2.3)
West Midlands	2057 (15.7)	278 170 (16.4)
East of England	413 (3.2)	66 446 (3.9)
London	2965 (22.6)	335 233 (19.8)
South East	2670 (20.4)	317 898 (18.8)
South West	1111 (8.5)	173 317 (10.2)
Unknown	0	234 (<0.1)
Ethnicity		
White	8769 (66.9)	1 106 974 (65.4)
Black	467 (3.6)	45 177 (2.7)
Asian	1651 (12.6)	108 603 (6.4)
Mixed	108 (0.8)	17 757 (1.1)
Other	329 (2.5)	34 726 (2.1)
Unknown	1781 (13.6)	380 026 (22.4)
Index of Multiple Deprivation (2019)		
Quintile 1 (least deprived)	2166 (16.5)	335 374 (19.8)
Quintile 2	2342 (17.9)	336 418 (19.9)
Quintile 3	2488 (19.0)	325 643 (19.2)
Quintile 4	2881 (22.0)	353 803 (20.1)
Quintile 5 (most deprived)	3221 (24.6)	340 894 (20.1)
Unknown	7 (<0.1)	1131 (0.1)
Smoking		
Current smoker	1690 (12.9)	293 016 (17.3)
Ex-smoker	3810 (29.1)	283 693 (16.8)
Never smoked	4196 (32.0)	532 804 (31.5)
Unknown	3409 (26.0)	583 750 (34.5)
BMI		
Underweight	94 (0.7)	13 657 (0.8)
Normal	1154 (8.8)	201 500 (11.9)

Continued

**Table 1** Continued

Characteristics	Hospitalised cohort (n=13 105) n (%)	Primary care cohort (n=1 693 263) n (%)
Overweight	2388 (18.2)	198 235 (11.7)
Obese	4586 (35.0)	215 802 (12.7)
Unknown	4883 (37.3)	1 064 069 (62.8)
Quan-Charlson Comorbidity Index (2005)		
Mean (SD)	1.0 (1.7)	0.2 (0.7)
0	7078 (54.0)	1 462 791 (86.4)
1–2	4232 (32.3)	197 557 (11.7)
3–4	1160 (8.9)	24 240 (1.4)
≥5	635 (4.9)	8675 (0.5)
Immunocompromised status		
Immunocompetent	12 924 (98.6)	1 629 716 (96.2)
Immunocompromised	181 (1.4)	63 547 (3.8)
Vaccination status: immunocompetent		
Unvaccinated	12 684 (98.1)	660 610 (40.5)
1 dose	240 (1.9)	125 129 (7.7)
2 doses	0	593 557 (36.4)
First booster dose	0	250 420 (15.4)
Vaccination status: immunocompromised		
Unvaccinated	102 (56.4)	1154 (1.8)
1 dose	79 (43.7)	5314 (8.4)
2 doses	0	33 731 (53.1)
3 doses	0	23 082 (36.3)
First booster dose	0	266 (0.4)
Risk of severe COVID-19		
McInnes Advisory Group	4323 (33.0)	250 329 (14.8)
PANORAMIC	11 011 (84.0)	691 593 (40.8)
Green Book	5341 (40.8)	212 556 (12.6)
COVID-19 severity*		
No oxygen therapy	9606 (73.3)	–
Low-flow oxygen	793 (6.1)	–
Non-invasive ventilation or high-flow oxygen	1859 (14.2)	–
Intubation/mechanical ventilation	822 (6.3)	–
Ventilation and additional organ support	25 (0.2)	–

*Highest level of severity experienced during the hospitalisation.
BMI, body mass index; GP, general practitioner.

Telephone consultations with a GP or nurse (n=5077; 38.7%) were more common than F2F consultations (n=2489; 19.0%) (online supplemental eTable 4). Telephone visits remained the main mode of consultation when stratified by age and risk definition, particularly for older adults, people at high risk of severe COVID-19 and immunocompromised patients. When assessing COVID-19-associated medication use, only 29 (0.2%) patients received a primary care prescription from their GP to manage or treat COVID-19 (online supplemental eTable

4). See online supplemental eTable 5 for primary care costs.

Primary care cohort

The proportion of patients with ≥1 F2F GP or nurse consultation was higher in the older age groups (aged ≥85 years: 12.7%; aged 18–49 years: 3.4%) (table 4). Similar patterns were observed for ≥1 telephone consultation; however, greater use was observed across all ages

Table 2 HCRU in the 4 weeks after index stratified by age, risk of severe COVID-19 and immunocompromised status at baseline among the hospitalised cohort

HCRU	Age stratifications					Risk criteria		Immunocompromised status at baseline
	All (n=13 105)	18–49 (n=3127)	50–64 (n=4844)	65–74 (n=2386)	75–84 (n=1690)	>85 (n=1058)	Green Book (n=5341)	Immunocompromised (n=181)
Length of hospital stay (in days)								
Mean (SD)	9.2 (10.0)	6.4 (8.1)	9.0 (10.1)	10.8 (10.9)	11.2 (10.2)	11.4 (9.7)	10.0 (9.8)	9.0 (6.7)
Median (Q1, Q3)	6.0 (4.0, 11.0)	5.0 (2.0, 7.0)	6.0 (4.0, 10.0)	8.0 (5.0, 13.0)	8.0 (5.0, 14.0)	8.0 (5.0, 15.0)	7.0 (4.0, 12.0)	7.0 (4.5, 12.0)
Critical care admission								
n (%)	1934 (14.8)	399 (12.8)	896 (18.5)	456 (19.1)	165 (9.8)	18 (1.7)	695 (13.0)	10 (5.5)
Length of stay in critical care								
Mean (SD)	11.5 (11.2)	9.7 (10.9)	12.3 (11.8)	12.3 (11.1)	10.0 (8.9)	5.3 (5.6)	11.2 (10.6)	9.0 (5.8)
Median (Q1, Q3)	8.0 (4.0, 15.0)	6.0 (4.0, 11.0)	8.5 (5.0, 16.0)	9.0 (5.0, 15.0)	8.0 (4.0, 14.0)	4.0 (1.0, 7.0)	8.0 (5.0, 14.0)	8.5 (4.0, 13.0)
Mechanical ventilation								
n (%)	792 (6.0)	135 (4.3)	398 (8.2)	204 (8.6)	55 (3.3)	0	278 (5.2)	<5
Mechanical ventilation days								
Mean (SD)	1.2 (0.5)	1.2 (0.4)	1.2 (0.4)	1.2 (0.5)	1.1 (0.4)	0	1.2 (0.4)	N/A
Median (Q1, Q3)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	0	1.0 (1.0, 1.0)	N/A
HCRU, healthcare resource utilisation.								

Table 3 Costs in the 4 weeks after index stratified by age, risk of severe COVID-19 and immunocompromised status at baseline among the hospitalised cohort

Costs	Age stratifications					Risk criteria		Immunocompromised status at baseline
	All (n=13 105)	18–49 (n=3127)	50–64 (n=4844)	65–74 (n=2386)	75–84 (n=1690)	≥85 (n=1058)	Green Book (n=5341)	Immunocompromised (n=181)
Healthcare cost per hospitalisation (£)								
Mean (SD)	13 059 (18659)	10 215 (16242)	14 396 (21874)	15 655 (20965)	12 500 (12409)	10 365 (6773)	13 009 (16509)	10 814 (8525)
Median (Q1, Q3)	8727 (4364, 13091)	7703 (2994, 11600)	8727 (4364, 14317)	8727 (4471, 17399)	8942 (5800, 13413)	8835 (5800, 13091)	8727 (4471, 13413)	8727 (5800, 13063)
Healthcare cost of non-critical care admission (£)								
Mean (SD)	9360 (7275)	7516 (6294)	9199 (7028)	10 366 (7990)	10 898 (7787)	10 876 (7308)	10 041 (7536)	10 283 (6511)
Median (Q1, Q3)	8727 (4364, 12799)	5800 (2259, 8942)	8727 (4364, 12561)	8727 (4364, 13091)	8942 (5800, 13091)	8942 (5800, 13413)	8727 (4364, 13091)	8727 (5800, 13091)
Healthcare cost of critical care admission (£)								
Mean (SD)	30 352 (35 116)	26 321 (34 702)	32 617 (37 578)	32 784 (33 219)	23 463 (25 529)	8501 (8689)	29 150 (31 633)	19 345 (15 827)
Median (Q1, Q3)	17 439 (9285, 39663)	11 332 (7555, 30 039)	19 569 (9444, 42 351)	22 421 (9444, 41 808)	16 999 (7474, 31, 356)	5617 (1482, 9444)	18 887 (9444, 38468)	14 551 (7555, 27 096)
Healthcare cost of critical care requiring mechanical ventilation (£)								
Mean (SD)	51 103 (42 055)	52 000 (43 415)	52 071 (44 628)	51 106 (37 077)	41 379 (36 238)	–	48 677 (38 050)	39 029 (23 487)
Median (Q1, Q3)	40 148 (23 517, 64 772)	39 860 (19 930, 77 057)	41 768 (24 912, 61 556)	39 860 (23 517, 67 263)	34 877 (18 291, 55 637)	–	38 981 (22 421, 61 200)	39 029 (22 421, 55 637)
Blank cells (ie, ‘–’) are due those aged >85 years not receiving mechanical ventilation.								

Table 4 HCRU in the 4 weeks after index stratified by age, risk of severe COVID-19 and immunocompromised status at baseline among the primary care cohort

HCRU	Age stratifications						Risk criteria		Immunocompromised status at baseline
	All (n=1 693 263)	18–49 (n=1 161 843)	50–64 (n=379 528)	65–74 (n=92 573)	75–84 (n=40 481)	≥85 (n=18 838)	Green Book (n=212 556)	Immunocompromised (n=63 547)	
Any COVID-19 medication use: n (%)	253 (<1.0)	69 (<1.0)	63 (<1.0)	33 (<1.0)	39 (0.1)	49 (0.3)	116 (0.1)	51 (0.1)	
Primary care consultations—F2F: number with >1 visit (%)	71 039 (4.2)	39 108 (3.4)	19 330 (5.1)	6491 (7.0)	3726 (9.2)	2384 (12.7)	17 237 (8.1)	4587 (7.2)	
Primary care consultations—telephone: number with >1 call (%)	137 148 (8.1)	70 675 (6.1)	40 311 (10.6)	13 434 (14.5)	7860 (19.4)	4868 (25.8)	36 852 (17.3)	9375 (14.8)	
F2F, face to face; HCRU, healthcare resource utilisation.									

(aged 18–49 years: 6.1%; aged ≥85 years: 25.8%) when compared with F2F consultations.

When assessing those at risk of severe COVID-19, we observed a similar proportion of patients with ≥1 F2F consultation across the three risk definitions (McInnes Advisory Group: 6.8%; PANORAMIC: 5.9%; Green Book: 8.1%) (see online supplemental eTable 6 for full details). However, the patterns of ≥1 telephone-based consultation slightly differed across the three risk definitions; with highest use noted for the Green Book criteria (17.3%) and lowest for the PANORAMIC criteria (12.4%). Of immunocompromised patients, 7.2% had at least one F2F consultation and 14.8% had at least one telephone consultation, in comparison to 4.1% and 7.8% for immunocompetent patients, respectively.

Among the primary care cohort, <1.0% (n=253) of patients received a primary care prescription for treatment of COVID-19.

The overall median costs were higher for F2F consultations compared with a telephone consultation among those with ≥1 primary care GP or nurse consultation: £39 (Q1, Q3: £7, £39) and £16 (Q1, Q3: £16, £16), respectively (table 5). These costs did not differ across the age, risk definition and immunocompromised status stratification for either the F2F or telephone consultations (see online supplemental eTable 7 for full details). The costs associated with treatment in the primary care setting were also analysed. Given the low prescribing associated with COVID-19 diagnoses in the primary care cohort, the associated medication costs were negligible, with the exception of costs among those who were immunocompromised (median cost: £21; Q1, Q3: £3, £566).

DISCUSSION

To the best of our knowledge, this is the first study to quantify HCRU and related costs specific to the acute phase of COVID-19 in all adults (both standard and high risk) within the primary and secondary care settings in England. Costs and HCRU were primarily driven by COVID-19-associated hospitalisations, particularly among older adults and those admitted to critical care, which imposed direct medical cost and resource use burden on the UK healthcare system.

Our findings on the overall LoS (6.0 days) were consistent with national estimates, indicating between August 2020 and March 2021 the median LoS ranged from 4 to 11 days.³⁵ However, our data only covered early waves of the COVID-19 pandemic, where LoS fluctuated over time due to varying factors such as variant predominance, changes in COVID-19 testing guidance and COVID-19 vaccinations.³⁶ For the patients admitted to critical care, we observed a median LoS of 8 days. A retrospective cohort study of patients admitted to ICU between March and May 2020 using COVID-19 Hospitalisation in England Surveillance System data found median LoS ranged from 10 to 12 days.³⁷ This lower LoS observed in our study might partly be explained by refinements made to the



Table 5 Costs in the 4 weeks after index stratified by age, risk of severe COVID-19 and immunocompromised status at baseline among the primary care cohort

Costs	Age stratifications					Risk criteria		Immunocompromised status at baseline
	All (n=1 693 263)	18–49 (n=1 161 843)	50–64 (n=379 528)	65–74 (n=92 573)	75–84 (n=40 481)	≥85 (n=18 838)	Green Book (n=212 556)	Immunocompromised (n=63 547)
Medication cost (£)								
Mean (SD)	165 (465)	242 (538)	204 (505)	134 (447)	187 (530)	8 (36)	161 (448)	486 (759)
Median (Q1, Q3)	2 (2, 4)	3 (2, 256)	2 (2, 24)	2 (2, 3)	3 (1, 10)	3 (1, 3)	3 (2, 9)	21 (3, 566)
Primary care consultations—F2F (£)								
Mean (SD)	27 (22)	26 (21)	28 (22)	27 (24)	27 (25)	27 (24)	28 (25)	28 (25)
Median (Q1, Q3)	39 (7, 39)	39 (7, 39)	39 (7, 39)	39 (7, 39)	39 (7, 39)	39 (7, 39)	39 (7, 39)	39 (7, 39)
Primary care consultations—telephone (£)								
Mean (SD)	18 (10)	17 (9)	18 (10)	18 (10)	19 (11)	20 (13)	19 (11)	18 (10)
Median (Q1, Q3)	16 (16, 16)	16 (16, 16)	16 (16, 16)	16 (16, 16)	16 (16, 16)	16 (16, 16)	16 (16, 16)	16 (16, 16)

F2F, face to face.

treatment and management of COVID-19 patients over the course of the pandemic, starting with the publication of critical care guidance in March 2020.^{38 39} Further, we found critical care LoS was not monotonic with age and therefore its associated costs, which is also aligned with previous studies.^{37 40} It is possible that the LoS observed in patients aged >85 years was biased due to survivorship with a shorter apparent LoS due to an increased risk of death in the older ages. The proportion of patients admitted to critical care (14.8%) and requiring MV (6.0%) was also consistent with published English estimates over a longer data coverage period (10.6% and 5.6%, respectively).⁴¹

Our cost estimates associated with COVID-19 hospitalisation are similar to those used by the National Institute for Health and Care Excellence Technology Appraisal assessing therapeutics for people with COVID-19, although the report restricted to severe COVID-19 patients and used non-comparable methodology.⁴² Data from other countries, for instance, a retrospective study of hospitalised COVID-19 patients in the USA from 1 April to 31 December 2020 using claims data, estimated the average cost per day for overall admissions and ICU admissions was \$1772 and \$2902, respectively,⁴³ with evidence from Italy reporting the hospitalisation cost per day varying based on the complexity of care (low complexity=€476; medium complexity=€700; high complexity=€1402).⁴⁴ However, the generalisability of these estimates to the UK population is limited given differences in populations, data coverage period, COVID-19 management strategies and healthcare systems. Notably, due to variability within the relatively smaller immunocompromised and hospitalised, it is likely that our findings related to costs in this group differ from existing studies.^{45–47} However, as these patients are at an increased risk of severe COVID-19, they are likely to experience high HCRU and costs. Also, very minimal differences in HCRU were found across the different high-risk groups that were either prioritised for treatment (highest risk group), eligible for the PANORAMIC clinical trial (PANORAMIC eligibility) or eligible for vaccination prioritisation (Green Book). All three subgroups incurred similar non-critical and critical care hospitalisation costs.

In the primary care setting, several major changes in the use of healthcare services occurred since the start of the pandemic, including: a reduction in health services (postponing non-urgent planned treatment and redeployment of NHS staff),⁴⁸ an increased use of telemedicine resulting from a change in policy (F2F appointments only when clinically necessary)⁴⁹ and a reluctance among patients to seek F2F care.^{50–52} These factors may explain the higher use of GP or nurse telephone consultation across both study cohorts, and overall limited use of GP or nurse consultations among the primary care cohort.

Our findings demonstrated that COVID-19-related hospitalisation continues to pose substantial pressure and cost to the healthcare system in England.⁹ This study reinforces the importance of continuing efforts with the UK COVID-19 vaccination programme in reducing

hospitalisation and severity of the disease.⁵³ Policy makers and healthcare professionals should persist with encouraging high vaccination coverage, specifically among vulnerable groups and those at higher risk of hospitalisation with COVID-19.⁵⁴

Limitations of the study

Our study has several limitations. First, while CPRD covers 24% of the population in England,⁵⁵ our previous published work found an under-representation of COVID-19 patients aged ≥ 65 years, particularly in the hospitalised cohort, and over-representation of patients living in specific English regions, such as London and the South East, for these two cohorts,¹⁹ and thus our findings should be interpreted with caution. Second, due to data latency, HES APC data were only available up to March 2021 and emergency department as well as outpatient data were unavailable. For patients in the primary care cohort after April 2021, hospitalisation status is unknown and therefore are unable to describe the HCRU and costs associated with more recent waves of the coronavirus pandemic. Cost estimates and LoS in the hospitalised immunocompromised patients should be interpreted with caution due to the smaller sample size, and therefore future research with a larger sample size is needed to better assess the HCRU and costs associated with this particular group. Lastly, our findings on the limited primary care prescriptions for the treatment of COVID-19 are expected given the first antiviral for COVID-19 in the UK was approved in November 2021,⁵⁶ which occurred towards the end of the study period,⁵⁷ the UK's stringent access criteria when compared with other countries, and due to our definition of medication use (prescription on the same day as a COVID-19 diagnosis).

Future studies with a larger sample size are required to better quantify the economic burden of COVID-19 among immunocompromised patients. Studies should also explore the consequences of post-COVID conditions, to incorporate other aspects of HCRU (eg, readmissions), and the indirect costs associated with COVID-19 such as employment-related sickness absence. Further, a better understanding of the health and social care needs of patients recovering from or who continue to experience symptoms of COVID-19 is required. While this study focuses on HCRU and costs at the patient level, further research estimating the national level might also be informative for policy development. Lastly, this study highlights the need to focus on specific populations, for example, those at risk of severe COVID-19; to better prepare for the next epidemic, future studies may consider assessing the economic impact of broader public health interventions, such as smoking prevention and weight loss programmes.

CONCLUSION

The present retrospective cohort study quantified COVID-19 HCRU and associated costs in England. Although the burden of COVID-19 has reduced following

the roll-out of COVID-19 vaccines in the UK, we observed substantial economic burden due to COVID-19 on the NHS. Importantly, this study showed much of the burden during the study period was driven by COVID-19-related hospitalisations, and that older adults are associated with higher burden. Findings from this study can be used to inform the long-term strategy for resource allocation in the management of COVID-19.

Acknowledgements Editorial/medical writing support under the guidance of the authors was funded by Pfizer and provided by Dr Gary Sidgwick, PhD, of Adelphi Real World, Bollington, UK, in accordance with Good Publication Practice 2022 (GPP 2022) guidelines (<https://www.ismpp.org/gpp-2022>). The authors gratefully acknowledge Tamuno Alfred, Darren Kailung Jeng and Chern Chuan Soo from Pfizer (New York, USA), Agnieszka Gajewska, Tomasz Mikołajczyk, Ewa Śleszyńska-Dopiera from Quanticate (Warsaw, Poland), and Olivia Massey from Adelphi Real World for statistical programming support.

Contributors JY conceptualised, designed, interpreted the data, revised and reviewed the manuscript. KMA designed, interpreted the data and reviewed the manuscript. KKR designed, interpreted the data and drafted the initial manuscript. TT, TM, CT, BEB, DM, LJM and PP interpreted the data and reviewed the manuscript. MR conducted the analyses, interpreted the data and reviewed the manuscript. RB, KN, MA, JLN and RW reviewed the manuscript. JLN conceptualised, revised and reviewed the manuscript. JY is the guarantor.

Funding Funding for this study was provided by Pfizer. The study protocol was developed collaboratively by Pfizer and Adelphi Real World. The protocol was independently reviewed and approved by CPRD's Research Data Governance (RDG) committee, and the analysis was conducted by Pfizer. Adelphi Real World wrote the manuscript, and both Pfizer and Adelphi Real World reviewed and approved the manuscript prior to submission.

Competing interests JY, KMA, MR, LJM, CT, TM, KN, DM, Tamuno Alfred, MA and JLN are employees of Pfizer and may hold stock or stock options. KKR, TT, PP, BEB and RW are employees of Adelphi Real World, which received funds from Pfizer to conduct the study and develop the manuscript.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Clinical Practice Research Datalink's Research Data Governance (CPRD study ID: 22_002062). This study involved the use of secondary data; no primary data collection was carried out for the purpose of this study. As all patient-level data were fully anonymised, and no direct patient contact or primary collection of individual patient data occurred, patient consent was not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Kathleen Michelle Andersen <http://orcid.org/0000-0003-2670-800X>
Bethany Emma Backhouse <http://orcid.org/0000-0001-6114-660X>
Robert Wood <http://orcid.org/0000-0002-6977-435X>

REFERENCES

- 1 Johns Hopkins University of Medicine. Coronavirus resource center dashboard. 2023. Available: <https://coronavirus.jhu.edu/>
- 2 GOV.UK. UK summary - Coronavirus (COVID-19) in the UK. 2023. Available: <https://coronavirus.data.gov.uk/>
- 3 National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2023. Available: <https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326>
- 4 World Health Organization (WHO). Therapeutics and COVID-19: living guideline. 2023. Available: <https://app.magicapp.org/#/guideline/nBkO1E/section/EKDKdj>
- 5 Soriano JB, Murthy S, Marshall JC, *et al*. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 2022;22:e102–7.
- 6 Wolff D, Nee S, Hickey NS, *et al*. Risk factors for COVID-19 severity and fatality: a structured literature review. *Infection* 2021;49:15–28.
- 7 Tazerji SS, Shahabinejad F, Tokasi M, *et al*. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. *Gene Rep* 2022;26:101505.
- 8 UK Health Security Agency (UKHSA). COVID-19: the green book, chapter 14A, Pg1–54. 2022. Available: <https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a>
- 9 GOV.UK. Direct and indirect health impacts of COVID-19 in England: emerging Omicron impacts. 2022. Available: <https://www.gov.uk/government/publications/direct-and-indirect-health-impacts-of-covid-19-in-england-emerging-omicron-impacts/direct-and-indirect-health-impacts-of-covid-19-in-england-emerging-omicron-impacts>
- 10 Cunningham JW, Vaduganathan M, Claggett BL, *et al*. Clinical outcomes in young US adults hospitalized with COVID-19. *JAMA Intern Med* 2021;181:379.
- 11 Di Fusco M, Shea KM, Lin J, *et al*. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *J Med Econ* 2021;24:308–17.
- 12 Lavery AM, Preston LE, Ko JY, *et al*. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, March–August 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1695–9.
- 13 Richards F, Kodjamanova P, Chen X, *et al*. Economic burden of COVID-19: a systematic review. *Clinicoecon Outcomes Res* 2022;14:293–307.
- 14 Keogh-Brown MR, Jensen HT, Edmunds WJ, *et al*. The impact of COVID-19, associated behaviours and policies on the UK economy: a computable general equilibrium model. *SSM Popul Health* 2020;12:100651.
- 15 Clinical Practice Research Datalink (CPRD). CPRD Aurum March 2022 (version 2022.03.001) [data set]. Clinical practice research datalink. 2022. Available: <https://doi.org/10.48329/MY9S-4X08>
- 16 Clinical Practice Research Datalink (CPRD). CPRD linked data 2022. 2022. Available: <https://cprd.com/cprd-linked-data>
- 17 Clinical Practice Research Datalink (CPRD). Release notes: CPRD Aurum. 2022. Available: <https://cprd.com/sites/default/files/2022-05/2022-05%20CPRD%20Aurum%20Release%20Notes.pdf>
- 18 Clinical Practice Research Datalink (CPRD). Feasibility counts for SARS-CoV-2-related codes in CPRD primary care data. 2022. Available: <https://cprd.com/sites/default/files/2022-05/SARS-CoV-2%20counts%20May2022.pdf>
- 19 Andersen KM, McGrath LJ, Reimbaeva M, *et al*. Persons diagnosed with COVID in England in the clinical practice research datalink (CPRD): a cohort description. *Epidemiology* [Preprint].
- 20 NHS Digital. Coronavirus test results now visible to GPs. 2020. Available: <https://digital.nhs.uk/news/2020/coronavirus-test-results-now-visible-to-gps>
- 21 Clinical Practice Research Datalink (CPRD). CPRD Aurum glossary of terms/data definitions V2.0. 2023. Available: <https://cprd.com/sites/default/files/2023-02/CPRD%20Aurum%20Glossary%20Terms%20v2.pdf>
- 22 Quan H, Sundararajan V, Halfon P, *et al*. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130–9.
- 23 World Health Organization (WHO). COVID-19 therapeutic trial synopsis. 2020. Available: <https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis>
- 24 NHS England. Interim clinical commissioning policy: treatments for non-hospitalised patients with COVID-19. 2022. Available: <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2022/11/C1710-interim-clinical-commissioning-policy-treatments-for-non-hospitalised-patients-with-covid-19-nov-22.pdf>
- 25 National Institute for Health and Care Excellence. *Managing COVID 19: treatments*. 2022.
- 26 NHS England. National cost collection for the NHS 2020/2021. 2021. Available: <https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/>
- 27 NHS Digital. Hospital admitted patient care activity. 2020. Available: <https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2020-21>
- 28 Personal Social Services Research Unit (PSSRU). Unit costs of health and social care. 2022. Available: <https://www.pssru.ac.uk/project-pages/unit-costs/>
- 29 NHS Business Services Authority (NHSBSA). Drug tariff 2022. n.d. Available: <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff>
- 30 Intensive Care National Audit and Research Centre (ICNARC). COVID-19 report 2023. 2023. Available: <https://www.icnarc.org/our-audit/audits/cmp/reports>
- 31 Ioannou GN, Locke E, Green P, *et al*. Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. *JAMA Netw Open* 2020;3:e2022310.
- 32 Department of Health and Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-Cov-2 when considering the use of Neutralising Monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. 2022. Available: <https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-mono-clonal-antibodies>
- 33 University of Oxford. PANORAMIC - help find effective early treatments for COVID-19. 2022. Available: <https://www.panoramictrial.org/>
- 34 Davidson JA, Banerjee A, Smeeth L, *et al*. Risk of acute respiratory infection and acute cardiovascular events following acute respiratory infection among adults with increased cardiovascular risk in England between 2008 and 2018: a retrospective, population-based cohort study. *Lancet Digit Health* 2021;3:e773–83.
- 35 The Nuffield Trust. Chart of the week: how long do COVID-19 patients spend in hospital? 2023. Available: <https://www.nuffieldtrust.org.uk/resource/chart-of-the-week-how-long-do-covid-19-patients-spend-in-hospital-1>
- 36 Yaesoubi R, You S, Xi Q, *et al*. Simple decision rules to predict local surges in COVID-19 hospitalizations during the winter and spring of 2022. *medRxiv* 2021;2021.12.13.21267657.
- 37 Shryane N, Pampaka M, Aparicio-Castro A, *et al*. Length of stay in ICU of COVID-19 patients in England, March - May 2020. *Int J Popul Data Sci* 2021;5:1411.
- 38 Bamford P, Bentley A, Dean J, *et al*. Intensive care society guidance for prone positioning of the conscious COVID patient. 2020. Available: <https://emcrit.org/wp-content/uploads/2020/04/2020-04-12-Guidance-for-conscious-prone.pdf>
- 39 National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults (Ng159). 2020. Available: <https://www.nice.org.uk/guidance/ng159>
- 40 Intensive Care National Audit and Research Centre (ICNARC). ICNARC report on COVID-19 in critical care. 2020. Available: <https://www.icnarc.org/DataServices/Attachments/Download/da626009-65bd-ea11-9127-00505601089b>
- 41 Thygesen JH, Tomlinson C, Hollings S, *et al*. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. *Lancet Digit Health* 2022;4:e542–57.
- 42 National Institute for Health and Care Excellence. Multiple technology appraisal - Therapeutics for people with COVID-19 [ID4038] committee papers. 2023. Available: <https://www.nice.org.uk/guidance/gid-ta10936/documents/committee-papers-2>
- 43 Ohsfeldt RL, Choong CK-C, Mc Collam PL, *et al*. Inpatient hospital costs for COVID-19 patients in the United States. *Adv Ther* 2021;38:5557–95.
- 44 Foglia E, Ferrario L, Schettini F, *et al*. COVID-19 and hospital management costs: the Italian experience. *BMC Health Serv Res* 2022;22:991.
- 45 Walker JL, Grint DJ, Strongman H, *et al*. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. *BMC Public Health* 2021;21:484.
- 46 Soley-Bori M, Ashworth M, Bisquera A, *et al*. Impact of multimorbidity on healthcare costs and utilisation: a systematic review of the UK literature. *Br J Gen Pract* 2021;71:e39–46.
- 47 Goldman JD, Robinson PC, Uldrick TS, *et al*. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of Immunotherapies. *J Immunother Cancer* 2021;9:e002630.

- 48 The Health Foundation. Non-COVID-19 NHS care during the pandemic - activity trends for key NHS services in England 12. 2020. Available: <https://www.health.org.uk/news-and-comment/charts-and-infographics/non-covid-19-nhs-care-during-the-pandemic>
- 49 Ahmed S, Sanghvi K, Yeo D. Telemedicine takes centre stage during COVID-19 pandemic. *BMJ Innov* 2020;6:252–4.
- 50 National Institute for Health and Care Research. How have GP practices adapted to the COVID-19 pandemic? 2020. Available: <https://arc-w.nihr.ac.uk/research/projects/collecting-rapid-covid-19-intelligence-to-improve-primary-care-response/>
- 51 The Health Foundation. Public confidence in using NHS returning but concerns persist among groups worst affected by COVID-19. 2020. Available: <https://www.health.org.uk/news-and-comment/news/public-confidence-in-using-nhs-returning-but-concerns-persist>
- 52 The Health Foundation. How has the COVID-19 pandemic impacted primary care? 2021. Available: <https://www.health.org.uk/news-and-comment/charts-and-infographics/how-has-the-covid-19-pandemic-impacted-primary-care>
- 53 Rahmani K, Shavaleh R, Forouhi M, *et al*. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis. *Front Public Health* 2022;10:873596.
- 54 Cook TM, Roberts JV. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. *Anaesthesia* 2021;76:608–16.
- 55 Wolf A, Dedman D, Campbell J, *et al*. Data resource profile: clinical practice research datalink (CPRD). *Int J Epidemiol* 2019;48:1740–1740g.
- 56 GOV.UK. First oral antiviral for COVID-19, Lagevrio (Molnupiravir), approved by MHRA. 2021. Available: <https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra>
- 57 GOV.UK. Government launches COVID-19 Antivirals Taskforce to roll out innovative home treatments this autumn. 2021. Available: <https://www.gov.uk/government/news/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn>